Cargando…

Does cost minimization of hypofractionated radiation therapy content all health stakeholders?

Detalles Bibliográficos
Autores principales:	Melidis, Christos, Seghour, Saliha, Noblet, Sandrine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. on behalf of Canadian Association of Medical Radiation Technologists. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266558/ https://www.ncbi.nlm.nih.gov/pubmed/37328357 http://dx.doi.org/10.1016/j.jmir.2023.05.042

Ejemplares similares

Cost Minimization Analysis of Hypofractionated Radiotherapy
por: Yaremko, Hannah L., et al.
Publicado: (2021)

Cost‐containment in hypofractionated radiation therapy: a literature review
por: Hunter, Darren, et al.
Publicado: (2018)

Hypofractionated Postmastectomy Radiation Therapy
por: Sayan, Mutlay, et al.
Publicado: (2020)

One Size Fits All: Does the Dogma Stand in Radiation Oncology?
por: Azria, David, et al.
Publicado: (2016)

Hypofractionated Radiation Therapy for Large Brain Metastases
por: Masucci, Giuseppina Laura
Publicado: (2018)

Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
por: Yang, Jing, et al.
Publicado: (2021)

Expanding on the multidisciplinary stakeholder framework to minimize harms for problematic risk-taking involving emerging technologies. •: Commentary on: Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms (Swanton et al., 2019)
por: Shi, Jing, et al.
Publicado: (2020)

Mild Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
por: Matsui, Toshiaki, et al.
Publicado: (2020)

Vestibular Schwannoma: Results of Hypofractionated Stereotactic Radiation Therapy
por: Pialat, Pierre-Marie, et al.
Publicado: (2021)

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions
por: Boyce-Fappiano, David, et al.
Publicado: (2022)

Cost containment analysis and access to treatment associated with adopting hypofractionated radiation therapy from the Brazilian perspective
por: Taylor, Prince, et al.
Publicado: (2022)

Implementation science issues in understanding, collecting, and using cost estimates: a multi-stakeholder perspective
por: Eisman, Andria B., et al.
Publicado: (2021)

Prerequisites for stakeholder framework: Consumer advocacy and health protection in the digital industry. •: Commentary on: Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms (Swanton et al., 2019)
por: Lee, Hae Kook
Publicado: (2020)

Rapamycin – “One size does not fit all”
por: Kallijärvi, Jukka, et al.
Publicado: (2019)

Hypofractionation of radiation dose to the prostate does not necessarily imply a greater risk of acute radiation proctitis
por: Ferini, Gianluca, et al.
Publicado: (2023)

All that is old does not wither: Conservation of outer kinetochore proteins across all eukaryotes?
por: Senaratne, Aruni P., et al.
Publicado: (2017)

In regard to “Radiation for glioblastoma in the era of COVID-19: Patient selection and hypofractionation to maximize benefit and minimize risk”
por: Rathod, Shrinivas, et al.
Publicado: (2020)

Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation
por: Green, Michael, et al.
Publicado: (2020)

The essential role of theory in minimizing harm from emerging technologies. Lost in committee?. •: Commentary on: Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms (Swanton et al., 2019)
por: Gullo, Matthew J., et al.
Publicado: (2020)

Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas
por: Elhammali, Adnan, et al.
Publicado: (2015)

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
por: Young, Kristina H., et al.
Publicado: (2016)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Antibiotics and extracorporeal circulation – one size does not fit all
por: Gonçalves-Pereira, João, et al.
Publicado: (2014)

Commentary: Aortic annuloplasty: One size does not fit all
por: Ouzounian, Maral, et al.
Publicado: (2021)

Commentary: A ventricular assist device that does it all—in theory
por: Woods, Ronald K.
Publicado: (2020)

Knowledge and potential impact of the WHO Global code of practice on the international recruitment of health personnel: Does it matter for source and destination country stakeholders?
por: Bourgeault, Ivy Lynn, et al.
Publicado: (2016)

Management of Pseudomonas aeruginosa pneumonia: one size does not fit all
por: Rello, Jordi, et al.
Publicado: (2014)

Is organic chemistry science – and does this question make any sense at all?
por: Kirschning, Andreas, et al.
Publicado: (2015)

Bony Tumors of the Cranial Base: One Size does not Fit All
por: Alimohamadi, Maysam
Publicado: (2018)

P-POSSUM for onco-surgeries: Does one suit fits all!
por: Garg, Rakesh, et al.
Publicado: (2022)

Commentary: One artery does not fit all: Tailoring the operation to the patient
por: Lawton, Jennifer S.
Publicado: (2021)

Does immune destruction drive all forms of bone marrow failure?
por: Dulmovits, Brian M., et al.
Publicado: (2022)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

Anticoagulation strategies in continuous kidney replacement therapy — does one size fit all?
por: Deep, Akash
Publicado: (2022)

Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy
por: Yamazaki, Hideya, et al.
Publicado: (2011)

Radiation Therapy for Palliation of Sarcoma Metastases: A Unique and Uniform Hypofractionation Experience
por: Soyfer, Viacheslav, et al.
Publicado: (2010)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter?
por: Yu, Jeong Il, et al.
Publicado: (2016)

Hyperfractionated and Hypofractionated Radiation Therapy for Human Malignant Glioma Xenograft in Nude Mice
por: Hasegawa, Masatoshi, et al.
Publicado: (1995)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b1qnailloptt7q3t3e0d484o1d